Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced liver fibrosis.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/first-glp-1-backed-mash-europe-2026a100032t?src=rss
Author :
Publish date : 2026-01-30 17:37:00
Copyright for syndicated content belongs to the linked Source.
